Regulatory press release

Prostatype Genomics publishes monthly newsletter and its net sales for the third quarter of 2023

Prostatype Genomics publishes a monthly newsletter with a company update by CEO Fredrik Persson and a long interview with CMO Gerald Andreoli about the clinical activities in the United States, including a large clinical validation study. At the same time, the company announces that its net sales for the third quarter of 2023 amounted to approx. 530 TSEK, compared to 109 TSEK for the same period last year.

Prostatype Genomics will, starting in December 2023, publish monthly newsletters to provide more comprehensive information to shareholders, investors and other interested parties about the company’s activities and progress. This is also expected to at some extent make up for the company’s decision to change to semi-annual reporting as a part of the company’s introduced efficiency program.

December’s monthly newsletter includes the following:

Company update with CEO Fredrik Persson
Fredrik comments, among other things, the company’s net sales (global sales figure) of approx. 530 TSEK for the third quarter, which is the company’s highest sales figure for a single quarter yet, albeit from low levels, the start of the clinical validation study in the United States, recently achieved milestones in the multicentre study in Spain, an ongoing study at Akademiska sjukhuset in Uppsala, Sweden, implementation of the announced program to increase cost efficiency, and the ongoing preferential rights issue.

Long read – Interiew with Prostatype Genomics’ CMO Gerald Andriole on the company’s clinical strategy in the United States
The company’s CMO Gerald “Jerry” Andriole talks about Prostatype Genomics’ ambitious clinical strategy in the United States, including the large clinical validation study constituting the most important project on the path towards achieving approval for reimbursement from Medicare. The interview also provides information about how Jerry perceives the usage of prognostic biomarkers for prostate cancer, what they contribute with as a factor when deciding on treatment, and why the market in the United States is so much further ahead compared to the European market.

To read the newsletter, and subscribe for upcoming issues, click on this link:

The company also wants to highlight a recent filmed presentation with the company’s CEO, that can be reached via this link:

All filmed presentations, interviews, articles and information about the ongoing preferential rights issue can be found on the company’s right issue webpage:

Prostatype Genomics- right issue webpage and newsletters are produced together with the IR communications agency Honeybadger,

For more information, please contact:

Fredrik Persson, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01

About Prostatype Genomics AB

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of diagnosed prostate cancer. The test was developed by a research group at Karolinska Institute, Stockholm, Sweden, and is provided by Prostatype Genomics AB.







This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 21-12-2023 18:33 CET.